Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
The difference is the social understanding.
Nobody gets thyroid-shamed. People understand hyper-/hypo-thyroidism as an objective symptom of a physiological problem.
Obesity is not viewed the same, though it really should be.